Combination of brimonidine and timolol for topical ophthalmic use

Abstract

Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.

1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . A method of reducing the adverse events experienced by a patient taking brimonidine comprising administering twice daily to the affected eye of the patient a single composition comprising 0.2% w/v brimonidine tartrate and 0.5% w/v timolol free base, wherein said method reduces the incidence of one or more adverse events, as compared to the administration of 0.2% w/v brimonidine tartrate monotherapy three times per day. 
     
     
         18 . The method of  claim 17 , wherein the adverse event is conjunctival hyperemia. 
     
     
         19 . The method of  claim 17 , wherein the adverse event is oral dryness. 
     
     
         20 . The method of  claim 17 , wherein the adverse event is eye pruritus. 
     
     
         21 . The method of  claim 17 , wherein the adverse event is allergic conjunctivitis. 
     
     
         22 . The method of  claim 17 , wherein the adverse event is foreign body sensation. 
     
     
         23 . The method of  claim 17 , wherein the adverse event is conjunctival folliculosis 
     
     
         24 . The method of  claim 17 , wherein the adverse event is somnolence.